Don’t Let Trade Issues Interfere With Drug Inspection Coordination, Experts Say
US National Academies panel diverges on how to focus pharmaceutical inspectorates’ mutual reliance arrangements on public health goals.
You may also be interested in...
20 years later, signs that this time the US EU mutual recognition agreement won’t fizzle.
Reliance on each other’s good manufacturing practice reports should allow EU and US regulators to better focus their limited inspection resources on drug manufacturers in other countries around the world.
Expert panel draws lessons from COVID-19 in pressing for new manufacturing technologies, greater global coordination, more resilient supply chains and trained vaccine plant workers ready to “parachute” into the next outbreak.